Turki Bandar Alotaibi

Department of Debrecen University, Riyadh, Saudi Arabia

Publications

• Reviews   
  Efficacy and Safety of using Rivaroxaban with Coronary Artery Disease Patients: Systematic Review and Meta Analysis
  Author(s): Turki Bjad Bensgayan, Turki Bandar Alotaibi, Razan Aish Almuhyawi, Waad Saed Almaramihi, Hanadi Salem Alwagdani, Maram Mohammed Mojammi, Doaa Mohammed Barnawi, Zainab Abdrabalnabi Almaa and Suzan Hasan Alotaibi
  
  Background: Rivaroxaban, an oral thing Xa inhibitor, is effective in treating venous thromboembolism, and has been shown to save you thromboembolic activities in atrial fibrillation. Low dose rivaroxaban prevents venous thromboembolism after orthopedic surgical procedures and acute coronary syndrome. Aim: This work aims to determine the efficacy and safety of using rivaroxaban with Coronary Artery Disease (CAD) patients. Materials & Methods: A systematic search was performed over different medical databases to identify Internal Medicine studies, which studied the outcome of the rivaroxaban group versus the Placebo group of CAD patients. We conducted a meta-analysis process on primary efficacy endpoint outcomes (death, Myocardial Infarction “MI”, stroke, or severe recurrent ischemia requiring revascularisation), and on .. Read More»